Related Experiment Video
Updated: Aug 14, 2026
04:44
Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease
Published on: June 16, 2020
First-Line Tocilizumab Monotherapy for Juvenile Systemic Sclerosis With Interstitial Lung Disease: A Case Report
Tadafumi Yokoyama1, Natsumi Inoue1, Satoshi Watanabe2
1Department of Pediatrics, Kanazawa University Hospital, Takara-Machi 13-1, Kanazawa Ishikawa, 920-8640, Japan, kanazawa-u.ac.jp.
Case Reports in Rheumatology
|August 13, 2026
Summary
Tocilizumab may help children with juvenile systemic sclerosis and interstitial lung disease. This treatment showed stable lung function and reduced lung abnormalities in a young patient over three years.
Area of Science:
- Pediatric Rheumatology
- Autoimmune Diseases
- Pulmonology
Background:
- Systemic sclerosis (SSc) in children often presents aggressively, with a high risk of interstitial lung disease (ILD).
- Tocilizumab, an anti-interleukin-6 receptor antibody, shows promise in adult SSc-ILD, but pediatric data is scarce.
Purpose of the Study:
- To evaluate the efficacy and safety of tocilizumab monotherapy in a pediatric patient with early-stage juvenile systemic sclerosis (jSSc) and ILD.
Main Methods:
- A 12-year-old girl with jSSc-ILD, characterized by Raynaud's phenomenon, puffy fingers, anti-topoisomerase I antibodies, reduced pulmonary function, and ground-glass opacities, received tocilizumab monotherapy.
- Clinical and radiological outcomes were monitored over 3 years.
Main Results:
- Tocilizumab treatment maintained stable pulmonary function.
- High-resolution computed tomography revealed partial resolution of interstitial lung changes.
- No significant adverse events, including severe infections or cytopenias, were reported.
Conclusions:
- Early tocilizumab initiation may be a viable therapeutic strategy for juvenile systemic sclerosis with interstitial lung disease.
- Further research is necessary to confirm its role and establish treatment guidelines for this rare condition.
Related Concept Videos
01:24Chronic Obstructive Pulmonary Disease
COPD is defined as a heterogeneous lung condition marked by persistent respiratory symptoms such as dyspnea, cough, and sputum production, caused by abnormalities in the airways that cause airflow obstruction.
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...
01:27Chronic Obstructive Pulmonary Disease-IV: Assessement and Diagnostic Studies
Assessing and diagnosing Chronic Obstructive Pulmonary Disease (COPD) involves a detailed approach that includes a comprehensive review of medical history, physical examination, and a variety of diagnostic tests. This thorough evaluation is essential to ensure an accurate diagnosis and guide effective management strategies.
Medical History
Medical History
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
01:19Chronic Obstructive Pulmonary Disease IV: Clinical Manifestations
Chronic Obstructive Pulmonary Disease, or COPD, is a long-term condition marked by persistent and only partially reversible airflow limitation. It involves two overlapping conditions—chronic bronchitis and emphysema—which often co-appear but differ in dominant symptoms and underlying mechanisms.Chronic Bronchitis FeaturesChronic bronchitis presents with a persistent productive cough and thick, sometimes purulent mucus due to airway inflammation, enlarged mucus glands, and goblet cell...
01:23Chronic Obstructive Pulmonary Disease I: Introduction
Chronic obstructive pulmonary disease is a common, preventable, and treatable respiratory disorder characterized by persistent symptoms and progressive airflow limitation. This limitation results from a combination of small-airway disease (obstructive bronchiolitis) and parenchymal destruction (emphysema), both driven by chronic inflammation from exposure to harmful particles or gases.The disease includes two main pathological entities: emphysema, marked by destruction of alveolar walls and...
01:20Chronic Obstructive Pulmonary Disease-I: Introduction
Chronic Obstructive Pulmonary Disease (COPD) is a long-lasting respiratory condition requiring continuous attention and care. It is a progressive lung disease that leads to breathing challenges due to airflow obstruction. It manifests as persistent respiratory symptoms and restricted airflow resulting from abnormalities in the airways and alveoli, usually due to long-term exposure to harmful particles or gases. COPD mainly consists of two primary conditions: emphysema and chronic bronchitis.